CPRIT suspends first cycle of awards for FY21

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer Prevention and Research Institute of Texas has suspended its first cycle of grant applications for fiscal year 2021 for Academic Research, Product Development Research and Prevention Program awards.

CPRIT is taking this action in response to the unexpected impact to the budget from the COVID-19 pandemic and a projected decrease in oil and gas revenues. CPRIT continues to evaluate releasing Requests for Applications for fiscal year 2021 and is committed to doing so if circumstances support it.

CPRIT has closed the FY 21.1 Academic Research Program RFAs listed below (originally due June 3). CPRIT will not accept applications responding to these RFAs and will withdraw any FY 21.1 applications already submitted.

Applications for the second cycle of fiscal year 2020 (FY 20.2) are undergoing peer review. CPRIT is not withdrawing the FY 20.2 applications and expects to announce awards in August or early fall.

  • RFA R-21.1 – RTA Research Training Awards

  • RFA R-21.1 – IIRA Individual Investigator Research Awards

  • RFA R-21.1 – IIRACCA Individual Investigator Research Awards for Cancer in Children and Adolescents

  • RFA R-21.1 – IIRACT Individual Investigator Research Awards for Clinical Translation

  • RFA R-21.1 – IIRACSBC Individual Investigator Research Awards for Computational Systems Biology of Cancer

  • RFA R-21.1 – IIRAP Individual Investigator Research Awards for Prevention and Early Detection

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login